Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IMMUNE LANDSCAPES PREDICT CHEMOTHERAPY RESISTANCE AND IMMUNOTHERAPY RESPONSE IN ACUTE MYELOID LEUKAEMIA

ABSTRACT: IMMUNE LANDSCAPES PREDICT CHEMOTHERAPY RESISTANCE AND IMMUNOTHERAPY RESPONSE IN ACUTE MYELOID LEUKAEMIA

PROVIDER: PRJNA555714 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

IMMUNE LANDSCAPES PREDICT CHEMOTHERAPY RESISTANCE AND IMMUNOTHERAPY RESPONSE IN ACUTE MYELOID LEUKAEMIA

Project description:Immunological classifiers that predict patient outcome and therapeutic responses have been constructed through targeted immune gene expression profiling of diagnostic bone marrow samples from patients with acute myeloid leukaemia.

2020-06-03 | GSE134589 | GEO

IMMUNE SENESCENCE PHENOTYPES PREDICT CHEMOTHERAPY RESISTANCE IN ACUTE MYELOID LEUKAEMIA

2022-09-16 | GSE176100 | GEO

Single-cell transcriptomic profiling reveals immune cell heterogeneity in acute myeloid leukaemia peripheral blood mononuclear cells after chemotherapy

Project description:Purpose Acute myeloid leukaemia (AML) is a heterogeneous disease characterised by the rapid clonal expansion of abnormally differentiated myeloid progenitor cells residing in a complex microenvironment. However, the immune cell types, status, and genome profile of the peripheral blood mononuclear cell (PBMC) microenvironment in AML patients after chemotherapy are poorly understood. In order to explore the immune microenvironment of AML patients after chemotherapy, we conducted this study for providing insights into precision medicine and immunotherapy of AML. Methods In this study, we used single-cell RNA sequencing (scRNA-seq) to analyse the PBMC microenvironment from five AML patients treated with different chemotherapy regimens and six healthy donors. We compared the cell compositions in AML patients and healthy donors, and performed gene set enrichment analysis (GSEA), CellPhoneDB, and copy number variation (CNV) analysis. Results Using scRNA-seq technology, 91,772 high quality cells of 44,950 PBMCs from AML patients and 46,822 PBMCs from healthy donors were classified as 14 major cell clusters. Our study revealed the sub-cluster diversity of T cells, natural killer (NK) cells, monocytes, dendritic cells (DCs), and haematopoietic stem cell progenitors (HSC-Prog) in AML patients under chemotherapy. NK cells and monocyte-DCs showed significant changes in transcription factor expression and chromosome copy number variation (CNV). We also observed significant heterogeneity in CNV and intercellular interaction networks in HSC-Prog cells. Conclusion Our results elucidated the PBMC single-cell landscape and provided insights into precision medicine and immunotherapy for treating AML.

2023-08-31 | GSE235857 | GEO

caArray_lau-00212: Expression profiles of osteosarcoma that can predict response to chemotherapy

Project description:Use of expression profiles of osteosarcoma to predict response to chemotherapy

2016-05-26 | GSE81892 | GEO

MicroRNA signature predict chemotherapy response in patients with advanced colorectal cancer

Project description:The aim of our study was to evaluate the ability of miRNA expression patterns to predict chemotherapy response in a cohort of 39 patients with metastatic colorectal carcinoma

2014-08-12 | GSE48664 | GEO

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.

Project description: Not available

| S-EPMC7427158 | biostudies-literature

Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression signature can be used to predict treatment efficacy in various types of tumour. We aim to identify a gene expression signature to predict efficacy of induction chemotherapy (IC) in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2021-04-14 | GSE132112 | GEO

Phosphoproteomic profiling of Acute Myeloid Leukaemia

Project description:Acute Myeloid Leukaemia (AML) carries a 5 year survival rate of just 24%. Toxic chemotherapy regimens remain the backbone of standard of care for AML. The FLT3 tyrosine kinase is a recognised AML oncogene, with FLT3 activating mutations occurring in approximately one third of all AML patients. However, therapeutic targeting of FLT3 has proven difficult as monotherapy, with the development of drug resistance and relapse. Characterisation of the signalling pathways regulated by mutant FLT3 is required to identify better therapeutic strategies.

2019-12-20 | MSV000084730 | MassIVE

Identification of HOXB8 and K LK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy

Project description:To measure global gene expression in primary advanced colorectal cancer patients who have undergone fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy and screen valuable biomarkers to predict the effects of chemotherapy Samples from primary advanced colorectal cancer patients were collected. The effects of chemotherapy were evaluated, and patients were divided into an experimental group and a control group.

2015-12-31 | GSE69657 | GEO

Bulk RNA-sequencing of soft tissue sarcomas from patients undergoing chemotherapy and/or immunotherapy

Project description:The tumor microenvironment plays a crucial role in soft tissue sarcoma development and response to therapy. We performed bulk RNA-sequencing of tumors from patients with soft tissue sarcomas undergoing chemotherapy and/or immunotherapy to identify gene expression signatures associated with response to treatment.

2023-12-12 | GSE213065 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data